Personal CFO Solutions LLC Grows Stake in Cencora, Inc. (NYSE:COR)

Personal CFO Solutions LLC raised its stake in shares of Cencora, Inc. (NYSE:COR) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,436 shares of the company’s stock after purchasing an additional 309 shares during the period. Personal CFO Solutions LLC’s holdings in Cencora were worth $547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Amundi lifted its position in Cencora by 30.8% in the fourth quarter. Amundi now owns 1,338,710 shares of the company’s stock worth $318,385,000 after buying an additional 314,846 shares during the last quarter. Permanent Capital Management LP purchased a new position in shares of Cencora during the 4th quarter worth about $267,000. Intellectus Partners LLC grew its holdings in Cencora by 6.6% during the 4th quarter. Intellectus Partners LLC now owns 3,260 shares of the company’s stock valued at $732,000 after purchasing an additional 202 shares during the last quarter. AMF Tjanstepension AB grew its holdings in Cencora by 147.4% during the 4th quarter. AMF Tjanstepension AB now owns 79,207 shares of the company’s stock valued at $17,799,000 after purchasing an additional 47,193 shares during the last quarter. Finally, Banco Santander S.A. bought a new stake in shares of Cencora during the fourth quarter worth $821,000. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the sale, the chief executive officer now owns 51,070 shares of the company’s stock, valued at $13,022,850. This trade represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,648 shares of company stock worth $2,862,342 in the last ninety days. Insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on COR. StockNews.com cut Cencora from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. upped their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Wells Fargo & Company raised their price objective on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Finally, Mizuho started coverage on Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $277.90.

Cencora Stock Performance

Shares of COR opened at $254.54 on Monday. The company’s 50 day simple moving average is $244.34 and its 200-day simple moving average is $238.39. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a market cap of $49.36 billion, a PE ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.86%. Cencora’s dividend payout ratio (DPR) is 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.